Literature DB >> 33561364

Ketamine and the Future of Rapid-Acting Antidepressants.

Lace M Riggs1,2, Todd D Gould2,3,4.   

Abstract

The therapeutic onset of traditional antidepressants is delayed by several weeks and many depressed patients fail to respond to treatment altogether. In contrast, subanesthetic ketamine can rapidly alleviate symptoms of depression within hours of a single administration, even in patients who are considered treatment-resistant. Ketamine is thought to exert these effects by restoring the integrity of neural circuits that are compromised in depression. This hypothesis stems in part from preclinical observations that ketamine can strengthen synaptic connections by increasing glutamate-mediated neurotransmission and promoting rapid neurotrophic factor release. An improved understanding of how ketamine, and other novel rapid-acting antidepressants, give rise to these processes will help foster future therapeutic innovation. Here, we review the history of antidepressant treatment advances that preceded the ketamine discovery, critically examine mechanistic hypotheses for how ketamine may exert its antidepressant effects, and discuss the impact this knowledge has had on ongoing drug discovery efforts.

Entities:  

Keywords:  (2R,6R)-hydroxynorketamine; BDNF; brain-derived neurotrophic factor; glutamate; ketamine; rapid-acting antidepressant; treatment-refractory depression

Mesh:

Substances:

Year:  2021        PMID: 33561364      PMCID: PMC8170851          DOI: 10.1146/annurev-clinpsy-072120-014126

Source DB:  PubMed          Journal:  Annu Rev Clin Psychol        ISSN: 1548-5943            Impact factor:   18.561


  138 in total

1.  In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine.

Authors:  E A ZELLER; J BARSKY
Journal:  Proc Soc Exp Biol Med       Date:  1952-11

2.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

3.  Effects of Mg2+ on recovery of NMDA receptors from inhibition by memantine and ketamine reveal properties of a second site.

Authors:  Nathan G Glasgow; Madeleine R Wilcox; Jon W Johnson
Journal:  Neuropharmacology       Date:  2018-05-12       Impact factor: 5.250

Review 4.  Clinical and biochemical heterogeneity of depressive disorders.

Authors:  J W Maas
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

Review 5.  The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review.

Authors:  Mark Sinyor; Ayal Schaffer; Anthony Levitt
Journal:  Can J Psychiatry       Date:  2010-03       Impact factor: 4.356

Review 6.  Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Authors:  Todd D Gould; Carlos A Zarate; Scott M Thompson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

7.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

8.  BDNF release and signaling are required for the antidepressant actions of GLYX-13.

Authors:  T Kato; M V Fogaça; S Deyama; X-Y Li; K Fukumoto; R S Duman
Journal:  Mol Psychiatry       Date:  2017-12-05       Impact factor: 15.992

9.  Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321

10.  Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.

Authors:  Chadi G Abdallah; Lynnette A Averill; Ralitza Gueorguieva; Selin Goktas; Prerana Purohit; Mohini Ranganathan; Mohamed Sherif; Kyung-Heup Ahn; Deepak Cyril D'Souza; Richard Formica; Steven M Southwick; Ronald S Duman; Gerard Sanacora; John H Krystal
Journal:  Neuropsychopharmacology       Date:  2020-02-24       Impact factor: 7.853

View more
  3 in total

Review 1.  Mechanisms of ketamine and its metabolites as antidepressants.

Authors:  Evan M Hess; Lace M Riggs; Michael Michaelides; Todd D Gould
Journal:  Biochem Pharmacol       Date:  2021-12-27       Impact factor: 5.858

Review 2.  [Rapid-acting antidepressants-neurobiological mechanisms of action].

Authors:  Peter Gass; Andrei N Vasilescu; Dragos Inta
Journal:  Nervenarzt       Date:  2021-11-11       Impact factor: 1.214

Review 3.  Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant.

Authors:  Songbai Xu; Xiaoxiao Yao; Bingjin Li; Ranji Cui; Cuilin Zhu; Yao Wang; Wei Yang
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.